证券日报网讯 2月25日，新天药业在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 人数为27416户。 （文章来源：证券日报） ...

每经AI快讯，ST香雪2月13日晚间发布公告称，公司第九届第三十三次董事会会议于2026年2月13日在 公司本部会议室以现场结合通讯方式召开。会议审议了《关于申请借款重组的议案》等文件。 每经头条（nbdtoutiao）——上市公司净利从暴增9倍到突然预亏超2亿元，董事长为何自掏5000万元补 窟窿？50亿元信托理财也去向成谜，股民直呼看不懂 （记者 王晓波） ...

证券日报网讯2月11日，新天药业（002873）在互动平台回答投资者提问时表示，截至2026年2月10日， 公司股东人数为27992户。 ...

Market Overview - A-shares showed resilience against external market pressures, with major indices recovering after a low opening, resulting in the Shanghai Composite Index rising by 4.40 points (0.11%) to 4080.31 points, the Shenzhen Component Index increasing by 90.46 points (0.65%) to 14043.17 points, and the ChiNext Index up by 21.17 points (0.65%) to 3281.45 points [1] Sector Performance - The chemical sector saw strong performance, with stocks like Cangzhou Dahua, Jinniu Chemical, Baichuan Co., and Baihehua hitting the daily limit [1] - The humanoid robot concept stocks were active, with companies such as Wuzhou Xinchun, Liancheng Precision, and Tianqi Co. also reaching the daily limit [1] - The non-ferrous metals sector showed signs of recovery, with Hunan Gold and Xianglu Tungsten hitting the daily limit [1] - The traditional Chinese medicine sector opened strong, with stocks like Te Yi Pharmaceutical reaching the daily limit [1] Policy Support - The Chinese government, through the Ministry of Industry and Information Technology and other departments, issued a development plan for the traditional Chinese medicine industry, aiming for a collaborative development system by 2030, which is expected to boost the sector's growth [2] Price Dynamics - The price of disperse dyes surged due to a significant increase in the cost of upstream key intermediates, rising from 25,000 yuan/ton to 38,000 yuan/ton, a more than 50% increase, which is expected to drive up prices in the textile dyeing industry as demand increases post-Spring Festival [3] Market Challenges - The liquor sector faced downward pressure, with stocks like Huangtai Liquor hitting the daily limit down, attributed to a decline in demand following the consumption peak around the Spring Festival and increased competition leading to price cuts [4] - AI application stocks experienced declines, with companies like Yaowang Technology and Zhejiang Wenhu falling to the daily limit due to concerns over technology maturity and unclear business models [5] - The optical module and CPO sectors continued to adjust, with stocks like Yuanjie Technology and Xinyisheng dropping over 6% as market expectations normalized [6] Institutional Insights - Zhongjin Securities noted that despite external pressures, there are no typical bull market top signals in Chinese stocks, with ample liquidity and improving earnings, suggesting a continued positive outlook for Chinese asset revaluation [7] - Tianfeng Securities highlighted the fragility of market sentiment, indicating that any news could trigger short-term sell-offs, particularly in the gold market [7] - Huachuang Securities observed a strong recovery in consumer markets expected for the 2026 Spring Festival, driven by government-led consumption initiatives, suggesting potential growth in sectors like dining, tourism, and retail [7]

（文章来源：证券日报） 证券日报网讯 2月2日，新天药业在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东人 数为27115户。 ...

Industry Overview - The gynecological medication industry encompasses drugs for the prevention, diagnosis, and treatment of gynecological diseases, including traditional hormone therapies, antibiotics, analgesics, and immunomodulators [1][3] - The market for gynecological medications in China has shown rapid growth, with the market size increasing from 27.735 billion yuan in 2012 to an estimated 56.137 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 6.05% [1][9] - By 2025, the market size is projected to reach approximately 59.53 billion yuan, driven by increasing awareness of women's health and societal emphasis on female health [1][9] Market Dynamics - The prevalence of gynecological diseases among adult women in China is high, with an estimated incidence rate between 40% and 70%, including conditions such as tumors, cysts, reproductive-related diseases, and gynecological inflammation [6] - The rise in gynecological disease rates and the growing health consciousness among women are contributing to the steady expansion of the gynecological medication market [6] Industry Chain - The gynecological medication industry chain consists of upstream raw materials, intermediates, and pharmaceutical equipment; midstream production; and downstream distribution through pharmacies, hospitals, and e-commerce platforms [6][7] Key Companies - Notable companies in the gynecological medication sector include Qianjin Pharmaceutical, Tongrentang, Kangyuan Pharmaceutical, Jiuzhitang, Yunnan Baiyao, and others, which are focusing on R&D and product differentiation [10][11] Development Trends - Future product development in gynecological medications is expected to shift towards precision and individualized treatment, utilizing diagnostic technologies to enhance treatment efficacy and reduce side effects [12] - Innovations in drug formulations and delivery methods will improve patient compliance and experience, with a focus on long-acting, user-friendly options [13] - The role of gynecological medication companies is evolving from mere drug suppliers to providers of comprehensive health management solutions for women throughout their life stages [14]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002873 证券简称：新天药业 公告编号：2026-005 贵阳新天药业股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、报告期内，受市场环境等因素影响，公司营业收入较上年同期下降，同时因部分原材料价格上涨， 导致公司的生产成本上升，对当期业绩造成一定影响。 2、2025年度非经常性损益对净利润的影响金额较上年同期下降，主要是2024年度公司处置"盐酸班布特 罗颗粒"药品上市许可及相关生产技术增加净利润约1,600万元。 公司将结合实际，除持续优化经营管理与营销推广策略，提升市场开发的精准度和有效性外，还将充分 利用药材价格分析预判和库存储备调节相结合的策略，减少原材料价格带来的成本增长压力。同时，多 方面提高内部管理效率，促进公司经营管理与盈利能力的改善。 四、风险提示 本次业绩预告是根据公司财务部门初步核算得出，未经审计机构审计，具体财务数据请以公司后续披露 的经审计的2025年年度报告为准。敬请广大投资者谨慎决策，注意投资风险。 1、 ...

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. expects a significant decline in net profit for 2025, primarily due to market conditions and rising production costs [1][2] Financial Performance - The company forecasts a net profit attributable to shareholders of between 7.5 million to 11 million yuan, representing a year-on-year decline of 78.98% to 85.67% [2] - The net profit after deducting non-recurring gains is expected to be between 4 million to 6 million yuan, reflecting a decrease of 82.92% to 88.61% compared to the previous year [2] - Basic earnings per share are projected to be between 0.0307 yuan and 0.0451 yuan [2] Reasons for Performance Decline - The decline in revenue is attributed to adverse market conditions and an increase in raw material prices, which have raised production costs [2][3] - The decrease in non-recurring gains is primarily due to the absence of profits from the disposal of a drug license that occurred in 2024, which contributed approximately 16 million yuan to net profit [3] Strategic Actions - The company plans to optimize its operational management and marketing strategies to enhance market development effectiveness [3] - It will implement strategies combining raw material price analysis and inventory adjustments to mitigate cost pressures from rising raw material prices [3] - The company aims to improve internal management efficiency to enhance operational management and profitability [3] Asset Transfer Announcement - The company intends to transfer four drug licenses and related production technologies to Guizhou Xinan Tang Group for a total of 14 million yuan [1][4] - The drugs involved in the transfer include "Nalejing Granules," "Nalejing Capsules," "Cold Cough Capsules," and "Regulating Blood Capsules," which are currently non-core products and have not achieved significant sales [4] - The transfer is expected to help the company focus on core strategic products and optimize its product pipeline [4]

Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range of 7.5 million to 11 million yuan, which represents a year-on-year decrease of 78.98% to 85.67% [1] Financial Performance - The projected basic earnings per share for 2025 are between 0.0307 yuan and 0.0451 yuan [1] - The decline in performance is attributed to a decrease in operating revenue compared to the previous year, influenced by market conditions and rising production costs due to increased raw material prices [1] Non-Recurring Gains - The impact of non-recurring gains on net profit is expected to decrease compared to the previous year, primarily due to the 2024 disposal of the "Salbutamol Granules" drug license and related production technology, which added approximately 16 million yuan to net profit [1] Strategic Response - The company plans to optimize its operational management and marketing strategies to enhance market development effectiveness [1] - It will utilize a strategy combining raw material price analysis and inventory adjustments to mitigate cost pressures from rising raw material prices [1] - The company aims to improve internal management efficiency to enhance operational management and profitability [1]

每经AI快讯，新天药业1月28日晚间发布公告称，公司第八届第四次董事会会议于2026年1月27日以通 讯表决的方式召开。会议审议了《关于对外转让药品上市许可及相关生产技术的议案》等文件。 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 （记者 王晓波） ...